Cefsepa 2 grams (Ceftriaxone Sodium Hydrate)

Adult administration

For adults and children over 12 years, administer 1–2 g (potency) of Ceftriaxone once daily by intravenous or intramuscular injection. For infections caused by serious or moderately sensitive pathogens, the dose may be increased up to 4 g (potency) once daily.

Child administration

In neonates (within 14 days of birth), administer 20–50 mg/kg (potency) once daily, not to exceed 50 mg/kg (potency). For infants and children (15 days to 12 years), dose based on weight.

This medication should not be mixed or co-administered with calcium-containing solutions or drugs. It should especially not be used in neonates due to the risk of precipitation when combined with calcium. It should not be administered to patients with an allergy to this medication or with hypersensitivity to cephalosporins or penicillins. This medication, which contains lidocaine, should not be administered intravenously. It should also not be used in neonates or premature infants with issues in bilirubin binding. Caution is advised in patients with a history of drug allergies, asthma, or skin rashes. Dosage adjustment is necessary for patients with impaired kidney function, and special caution is required for elderly patients or those with a poor overall condition. This medication may cause side effects such as diarrhea, rash, liver dysfunction, and decreased blood cell counts; therefore, any unusual symptoms should be reported immediately. If severe allergic reactions or shock symptoms occur, administration should be discontinued and emergency treatment sought. Regular monitoring of liver, kidney, and blood tests is essential during treatment. This medication may cause dizziness affecting driving or machine operation, so caution is needed. When used with other drugs, it may affect kidney function, so consultation with a physician is necessary. During pregnancy or breastfeeding, the benefits and risks of treatment should be carefully considered before administration. Use in neonates and premature infants is not safe due to the risk of bilirubin encephalopathy. This medication should be used as soon as possible after preparation and can be refrigerated if necessary.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with fever, blisters, skin peeling, pain in mouth/eye mucous membranes, difficulty breathing or shortness of breath, asthma attack, respiratory abnormalities with cough + fever, yellowing of skin or eyes (jaundice), severe lethargy, sudden and severe headache, thunderclap headache, seizures, confusion, visual disturbances, paralysis, urination issues

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This medication should be stored in a sealed container to prevent exposure to air, and it is best stored at room temperature between 1°C and 30°C. This storage method maintains the medication's efficacy and prevents degradation.

Appearance

A white to light yellow crystalline powder filled in a colorless transparent vial

Package unit

1 vial, 10 vials